The FDA has expanded the designation of adalimumab-adbm (Cyltezo, Boehringer Ingelheim) to include interchangeable status—marking the second such approval to date.
The drug, which was initially approved in 2017, is now biosimilar to and interchangeable with adalimumab (Humira, AbbVie). Cyltezo is one of six biosimilar agents scheduled to reach the market by 2023, according to the Center for Biosimilars
OCTOBER 19, 2021